Saniona Investor Relations Material

Saniona AB engages in the research, development, and commercialization of treatments for the central nervous system. The company's products include Tesofensine, a monoamine reuptake inhibitor; Tesomet, a fixed dose combination of tesofensine and metoprolol; SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. Saniona AB (publ) has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS